Skip to main content

Table 4 Toxicities

From: Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice

Toxicitya, n (%) Grade of toxicity p1
G1 G2 ≥ G3 G0 vs G1–2 vs G3–5 G1–2 vs other G3–5 vs other
Anemia
 IRD (n = 75) 32 (42.7%) 23 (30.7%) 9 (12.0%) 0.065 0.093 0.021
 RD (n = 129) 43 (33.3%) 36 (27.9%) 33 (25.6%)
Neutropenia
 IRD (n = 74) 22 (29.7%) 13 (17.6%) 21 (28.4%) 0.701 0.771 0.406
 RD (n = 130) 48 (36.9%) 17 (13.1%) 30 (23.1%)
Thrombocytopenia
 IRD (n = 75) 23 (30.7%) 9 (12.0%) 16 (21.3%) 0.744 0.661 0.863
 RD (n = 128) 46 (35.9%) 14 (10.9%) 29 (22.6%)
Thrombosis/
Thrombus/Embolism
 IRD (n = 64) 3 (4.7%) 3 (4.7%) 0.460 1.000 0.349
 RD (n = 116) 6 (5.2%) 1 (0.9%) 2 (1.7%)
Fatigue
 IRD (n = 73) 18 (24.7%) 29 (39.7%) 5 (6.8%) 0.744 0.547 0.607
 RD (n = 127) 28 (22.0%) 47 (37.0%) 12 (9.4%)
Infection
 IRD (n = 70) 9 (12.9%) 26 (37.1%) 15 (21.4%) 0.008 0.005 1.000
 RD (n = 124) 11 (8.9%) 25 (20.2%) 28 (22.5%)
Neuropathyb
 IRD (n = 75) 27 (36.0%) 12 (16.0%) 3 (4.0%) 0.011 0.144 0.049
 RD (n = 128) 42 (32.8%) 10 (7.8%)
Nausea, vomiting
 IRD (n = 67) 21 (31.3%) 11 (16.4%) 0.062 0.041 0.535
 RD (n = 119) 25 (21.2%) 13 (11.0%) 2 (1.7%)
Anorexia
 IRD (n = 67) 19 (28.4%) 3 (4.5%) 0.400 0.398 0.537
 RD (n = 119) 17 (14.3%) 14 (11.8%) 2 (1.7%)
Diarrhea
 IRD (n = 69) 14 (20.3%) 9 (13.0%) 1 (1.4%) 0.026 0.052 0.369
 RD (n = 118) 12 (10.2%) 11 (9.3%)
Constipation
 IRD (n = 65) 7 (10.8%) 1 (1.5%) 1.000 1.000
 RD (n = 115) 8 (7.0%) 6 (5.2%)
Exanthema/rash
 IRD (n = 4) 3 (75.0%) 1 (25.0%) 1.000 1.000 1.000
 RD (n = 2) 2 (100.0%)
Other (max. grade)
 IRD (n = 48) 5 (10.4%) 34 (70.8%) 9 (18.8%) 0.185 0.185 0.185
 RD (n = 60) 9 (15.0%) 32 (53.3%) 19 (31.7%)
  1. a Evaluated only for patients with terminated treatment IRD or RD. Including patients (N = 1 for IRD and N = 4 for RD) who were excluded from other analyses due to switch associated with toxicity
  2. bIncludes both previous and newly acquired neuropathy
  3. 1 p-value of Fisher’s exact test